Editorial board member Enrico Heffler (Humanitas University, Milan, Italy) considers the increasing evidence that both oral and inhaled corticosteroids can lead, particularly in severe asthmatics, to adverse events that have a significant impact on both patients quality of life and health-related costs.
Part 11. What proportion of patients with asthma are classified as having severe disease? (0:12)
2. What adverse effects are associated with the use of oral and inhaled corticosteroids in patients with severe asthma? (2:19)
Part 21. What are the impact of these adverse effects in terms of patient quality of life and overall expense? (0:12)
2. What effective strategies may be used to minimise the use of corticosteroids in these patients? (2:01)
3. What new treatment strategies are emerging for patients with severe asthma? (3:14)
Speaker disclosure: Enrico Heffler has nothing to disclose in relation to this video interview.
Filmed at the European Respiratory Society (ERS) International Congress 2018, Paris, France, September 2018.